Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for hematologic disorders, particularly myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. The company's pipeline centers on monoclonal antibodies that target mutant forms of the calreticulin protein (mutCALR), with its lead candidate DMR-001 designed to inhibit mutCALR driven cell proliferation while sparing healthy cells. Damora Therapeutics, Inc. also holds options to develop additional mutCALR targeted candidates DMR-002 and DMR-003 under a collaboration agreement with Paragon Therapeutics, Inc. Following the Asset Acquisition completed in November 2025, the company assumed the rights and obligations related to the Paragon Option Agreement, which provides exclusive worldwide development and commercialization rights for these product candidates. The addressable market for mutCALR driven essential thrombocythemia and myelofibrosis in the United States is estimated at approximately five billion dollars, based on prevalence figures of about 140,000 essential thrombocythemia patients and 20,000 myelofibrosis patients. Damora Therapeutics, Inc. aims to build a portfolio of mutation directed therapies to address the full spectrum of mutCALR driven MPN disease.

Damora Therapeutics, Inc. has not yet commercialized any products and therefore does not generate revenue from sales. The company funds its research and development activities through equity financings, including a private placement that raised $285 million and a subsequent public offering that yielded approximately $297.3 million in net proceeds. These proceeds are allocated to preclinical studies, clinical trials, manufacturing support, working capital, and general corporate purposes. The funds also support IND enabling studies, manufacturing scale up activities, and preparation for potential commercial launch.

Damora Therapeutics, Inc. operates in a competitive landscape of biopharmaceutical firms pursuing mutCALR directed therapies for essential thrombocythemia and myelofibrosis. Key competitors include Incyte with its investigational antibody INCA033989, Janssen Pharmaceuticals with JNJ-88549968, Meiji Seika Pharma's mutCALR T cell engager, Prelude Therapeutics' mCALR CDK9d DAC, Alethio Therapeutics' AT-02, PharmaEssentia's ropeginterferon alfa-2b, Merck's bomedemstat, Novartis' pelabresib, Geron's imetelstat, and Kartos Therapeutics' navtemadlin. Current standard of care for these diseases includes agents such as hydroxyurea, anagrelide, interferon, and JAK inhibitors like ruxolitinib, which are not approved for essential thrombocythemia in the United States and are associated with various toxicities. Damora Therapeutics, Inc. differentiates itself through DMR-001's enhanced potency against both type 1 and type 2 mutCALR mutations, an extended half life enabling subcutaneous dosing, and a selective mechanism that aims to avoid the toxicities associated with non specific cytoreductive agents. The company believes that these attributes position DMR-001 as a potential best in class therapy for the mutCALR driven MPN market, addressing a significant unmet medical need.

Damora Therapeutics, Inc. intends to serve patients diagnosed with essential thrombocythemia and myelofibrosis, as well as the healthcare providers, hospitals, and clinics that treat these conditions. According to the filing, the prevalence of essential thrombocythemia in the United States is approximately 140,000 patients and the prevalence of myelofibrosis is approximately 20,000 patients. While the filing does not disclose specific customer names, the target population comprises individuals with mutCALR driven MPNs who require long term management of platelet overproduction, spleen enlargement, and related symptoms.